Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I was surprised it did that. Lets see tomorrow
I might need to buy more. These prices are a gift.
I know the market is having a bloodbath
Loving this price
I said this before. This is the only ticker I trust.
Is that the best you have. (She sells shares to tweet) still in this sell all you want. I will grab all of them
Playing around with the Ken-charts very cool
Great news!
If they do there job right we can hit 1.20. Every thing filed on time good revenue. 15 million this year. We can even trade at QB
once we break trough 9-10 we can hit 16-19
Lots of good Tweets. good strong hold. good sign for another leg up.
New Tweet!!!!!
More on this image later as we are getting ready to roll out an early iOS version of KenCharts. We decided that rather than waiting for all of the enhancements to be completed, we can complete some after the beta launch. #CEOtalk $APTY #KenCharts #Traders pic.twitter.com/4lHRTrysip
— APT Systems Inc APTY (@APTYsys) January 11, 2018
More on this image later as we are getting ready to roll out an early iOS version of KenCharts. We decided that rather than waiting for all of the enhancements to be completed, we can complete some after the beta launch. #CEOtalk $APTY #KenCharts #Traders
That’s is why I am not worried. Just another reason why we are going to surpass 1.00 dollar.
Waiting patiently.
Lets get ready. Big things are coming.
Great tweet from APTY. thank you for keeping us informed.
that's usually when the magic happens APTY long
that's what i am talking about. same thing happened. and one day boom i was jumping up and down like a child lol same share structure. or pretty close.
i have seen this before with my other ticker. next thing i saw was .015 and the day after .034 very excited to see that happen hear. lets go!!!!!!
Yes sir.
I picked up some more.
im ready. i know you are to lol. lets go to 10 cents first stop then 15.
RALEIGH, N.C., Jan. 2, 2018 -- Effective December 18, 2017 - LandStar, Inc. has been renamed to: DATA443 Risk Mitigation, Inc.
Mr. Jason Remillard has been named Chairman of the Board, CEO and President.
"The new company name and branding represents the central focus of the organization data security & risk mitigation technologies and solutions. We are immediately engaging on our rebranding, funding and acquisitions plan. Our strategy is to grow our market presence and capabilities for customers via product development and product/company acquisitions. GDPR and existing cyber-threats are creating an incredible opportunity for solution providers to demonstrate capabilities that enable businesses to function in this increasingly hostile environment," stated Mr. Remillard at the time of the announcement.
Mr. Remillard most recently has developed the industry-leading ClassiDocs structured and unstructured data classification & governance platform. Formerly a VP of Security Architecture at Deutsche Bank he was responsible for Big Data, Security Architecture, Engineering and Analytics. He was also product manager with Dell Software (formerly Quest Software) managing products from the Enterprise Identity and Access Management portfolio where he grew CAGR 20-90% over time. He has been in Internet and Enterprise security for over 25 years - including stints at IBM, Novell, Merrill Lynch, RBC, TD Bank, TUCOWS and Ellacoya Networks. He is also a founding member of the Blockchain Executive Group and holds an MBA from the Richard Ivey School of Business - University of Western Ontario, Canada.
"CISO, CSO and other security and compliance executives are increasingly looking for integrated product solution offerings that offer a faster time to deploy with reductions in operational expense. As well, SaaS-based cyber security (SECaaS) offerings are becoming more accepted as technologies and risk mitigation approaches mature," adds Mr. Remillard.
"We fully expect to take advantage of this increasingly large and complex market opportunity," finished Mr. Remillard. "We will also be announcing members of our Strategic Advisory Board with Industry, Business and Financial experts that will be heavily leveraged during our aggressive growth phases."
About DATA443 Risk Mitigation, Inc.
DATA443 Risk Mitigation, Inc. (http://www.data443.com) is a technology holding company that is actively developing and acquiring cyber-security products & service offerings that are central to cyber data security, GDPR, compliance and governance capabilities. The Company develops its own technologies and has an active acquisitions program in place.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See DATA443 Risk Mitigation, Inc.'s filings with the SEC, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
SOURCE DATA443 Risk Mitigation, Inc.
Related Links
http://www.data443.com
We are ready to break the 3 cent mark.
hey guys i got in last week. Pink trading pre market. Mhmmmm thats a good sign .
Good morning to everyone on the board. lets have a strong green day before the New Year!
i cant wait to get my shares for the new company. free shares. VPOR you haven't done me wrong yet. back on track. lets start the new years of right. best of luck to all the new hands and the old ones.
This Morning's Technical Outlook on Biotech Stocks -- Alnylam Pharma, Celldex Therapeutics, Aduro BioTech, and Zosano Pharma
NEW YORK, Dec. 27, 2017 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ALNY, CLDX, ADRO, and ZSAN which can be accessed for free by signing up to http://www.wallstequities.com/registration. Wall Street is holding its breath for the rekindling of mergers and acquisitions across the Biotechnology and Pharmaceutical sector after 2017 led to a pause in deal-making, reported Bloomberg. Tax reform, particularly a lower levy on US companies overseas cash, may be the key to driving the return of M&A in 2018, according to the article. This morning, research reports have been issued by WallStEquities.com on Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Celldex Therapeutics Inc. (NASDAQ: CLDX), Aduro BioTech Inc. (NASDAQ: ADRO), and Zosano Pharma Corp. (NASDAQ: ZSAN). All you have to do is sign up today for this free limited time offer, click the link below. http://www.wallstequities.com/registration
Alnylam Pharmaceuticals
Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc.'s shares gained 0.58%, closing Tuesday's trading session at $124.68. The stock recorded a trading volume of 407,321 shares. The Company's shares have advanced 11.26% over the previous three months and 233.01% since the start of this year. The stock is trading 41.62% above its 200-day moving average. Additionally, shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, have a Relative Strength Index (RSI) of 49.91.
On December 18th, 2017, Alnylam Pharma and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of adults with hereditary transthyretin-mediated amyloidosis. Patisiran was previously granted accelerated assessment by the EMA, potentially reducing the Agency's evaluation time from 210 to 150 days. Get the full research report on ALNY for free by clicking below at: http://www.wallstequities.com/registration/?symbol=ALNY
Celldex Therapeutics
On Tuesday, shares in Hampton, New Jersey headquartered Celldex Therapeutics Inc. recorded a trading volume of 781,342 shares. The stock rose 2.82%, ending the day at $2.92. The Company's shares have advanced 0.69% in the past month and 7.35% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 3.99% and 3.80%, respectively. Furthermore, shares of Celldex Therapeutics, which focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics, have an RSI of 55.02.
On November 30th, 2017, Celldex Therapeutics announced that enrollment has opened in its open-label, Phase-1 study of CDX-1140 in patients with advanced solid tumors. CDX-1140 is a fully human antibody targeted to CD40, a key activator of immune response that is found on dendritic cells, macrophages, and B cells, and is also expressed on many cancer cells. CLDX's complimentary research coverage is a few simple steps away at: http://www.wallstequities.com/registration/?symbol=CLDX
Aduro BioTech
Berkeley, California headquartered Aduro BioTech Inc.'s stock finished the day 3.73% lower at $7.75 with a total trading volume of 382,744 shares. The stock is trading below their 50-day moving average by 8.88%. Shares of the Company, which focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases, have an RSI of 37.96.
On December 13th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $18 a share to $9.50 a share.
On December 20th, 2017, Aduro BioTech announced that the US Patent and Trademark Office has issued a new patent in the Company's portfolio, related to the activation of the STING (Stimulator of Interferon Genes) pathway. US Patent 9,840,533 licensed from Memorial Sloan Kettering, The Rockefeller University, Rutgers, The State University of New Jersey, and University of Bonn covers pioneering composition of matter claims to a broad class of cyclic dinucleotide structures that induce STING-dependent immune responses. Register for your free research report on ADRO at: http://www.wallstequities.com/registration/?symbol=ADRO
Zosano Pharma
Shares in Fremont, California headquartered Zosano Pharma Corp. ended yesterday's session 9.28% lower at $0.59. The stock recorded a trading volume of 779,388 shares. The Company's shares are trading 15.18% below their 50-day moving average. Moreover, shares of Zosano Pharma, which develops a proprietary intracutaneous delivery system to administer drugs through the skin for rapid symptom relief to patients, have an RSI of 42.84.
On December 15th, 2017, Zosano Pharma announced that Bruce Steel has tendered his resignation from the Board of Directors, effective immediately. Following up on Mr. Steel's resignation, the number of Board of Director seats has been reduced to five. Wall St. Equities' downloadable research report on ZSAN available at: http://www.wallstequities.com/registration/?symbol=ZSAN
--
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
https://c212.net/c/img/favicon.png?sn=IO77483&sd=2017-12-27 View original content:http://www.prnewswire.com/news-releases/this-mornings-technical-outlook-on-biotech-stocks----alnylam-pharma-celldex-therapeutics-aduro-biotech-and-zosano-pharma-300575454.html
SOURCE Wall St. Equities
Smart play. Been hear since the run a few months back. It should happen again.
can you post this information on the board. that would be very helpful
Well I know it’s 500 million I see that on the otc website. I am asking how did we get a billion?
Morning all
Good Morning.
did you count how many shares were sold? serious question.
I can’t wait to be in the teens once again. And start of the New Years right.
i am waiting to see what happens after New Year.
still in it.
i am starting to realize out of all these stocks APTY is the most transparent. and the mind boggling thing is they are a real company. hear is to 2018
I don’t mind I averaged down. Lets go to .50 cents
I don't worry about the management, not one bit